RxDoctor Payments Data

James Parker, MD

Dermatology · Tupelo, MSNPI 1235759002

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by UCB, Inc. at 25.8% of the total. 2025 is the largest year on record at $1,961, more than ten times the $14 reported in 2023. That places this record below the midpoint for dermatology clinicians in MS, where the typical reported total is $4,621.

$2,256in general payments, 2019–2025

Across 129 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$581
  • LEO Pharma Inc.$312
  • Johnson & Johnson$283
  • Mallinckrodt Hospital Products Inc.$182
  • Novartis$173
  • AbbVie$169
  • plus $555 from 10 others

What the payments were for

  • Food & beverage$2,23699%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,256 in reported general payments places this provider in the 35th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$92,326
Medicare patients
329
Services billed
1,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab22$80,102
OtezlaApremilast16$76,146
Triamcinolone Acetonide193$4,070
Betamethasone Dipropionate46$2,851
Tacrolimus29$2,785
Fluorouracil40$2,744
Calcipotriene17$2,296
Clobetasol Propionate32$1,801
Ketoconazole125$1,758
Desonide15$1,194
Doxycycline Hyclate32$1,189
Metronidazole16$974
Fluocinonide18$845
Dapsone15$746
Doxycycline Monohydrate11$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$86$76,14616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →